Ben Beerle

Cooley advised Red Canary, a top managed detection and response platform that investigate threats while streamlining workflows through automated remediation, on its acquisition by Zscaler (Nasdaq: ZS).

Cooley advised BioMarin Pharmaceutical (Nasdaq: BMRN), a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient, on its definitive agreement to acquire Inozyme Pharma for $4 per share in an all-cash transaction valued at approximately $270 million.

Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.

Cooley advised Candid Therapeutics, a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, on its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004.

Cooley advised Accel, a long-standing investor of Squarespace, in connection with Squarespace’s definitive agreement to go private by Permira in an approximately $6.9 billion all-cash transaction.